Decision to list interventional radiology products supplied by Bard Australia Pty Ltd
9 November 2018
What we are doing
We are pleased to announce the approval of a listing agreement for a range of interventional radiology products with Bard Australia Pty Ltd (“Bard”).
In summary this will result in:
- 1227 Interventional Radiology products from Bard being listed in Part III of Section H of the Pharmaceutical Schedule from 1 December 2018.
- No additional expenditure on the purchase of Bard’s Interventional Radiology products, assuming no change to current usage levels or product mix.
This Agreement would supersede any existing DHB contracts with this supplier for the devices listed in the Schedule 1 of the Agreement.
Any changes to the original proposal?
This decision was subject to consultation with a letter dated 26 September 2018. No changes were made to the listing agreement as a result of consultation feedback.
During the consultation period PHARMAC was advised of duplicate devices and that some devices had been omitted from Bard’s device listings spreadsheet. Schedule 1 of the Agreement was amended to correct this.
Who we think will be most interested
- DHB staff
- Interventional radiology staff
- Procurement Officers
- Suppliers and Wholesalers
Detail about this decision
After completing the RFP evaluation, and consulting on the provisional agreement reached with Bard, PHARMAC has decided to list Bard’s range of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 December 2018.
DHBs that purchase Bard’s Interventional Radiology Products must do so under the terms and conditions, and at the prices, included in the Agreements, from 1 December 2018.
DHBs can continue to choose which Interventional Radiology Products they purchase.
Bard’s products are the most recent Interventional Radiology products that PHARMAC has decided to list on the Pharmaceutical Schedule. Further consultations in this category are expected over the next few months.
Our response to what you told us
We appreciate the time people took to respond to this consultation.
A summary of the main themes raised in feedback and our responses to the feedback received are set out below:
PHARMAC Staff Comment
Ministry of Health advising no technical resource impacts anticipated as a result of proposal
Noted Bard had recently been acquired by BD and queried whether Interventional Radiology products would be purchased via BD, or directly from Bard
PHARMAC staff contacted Bard and was advised that Interventional Radiology products would continue to be purchased directly from Bard for the foreseeable future.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 2 May 2019